Genetic ablation of Tnfα demonstrates no detectable suppressive effect on inflammation-related mouse colon tumorigenesis

Chemico-Biological Interactions

Volumn 184, Issue 3, 2010, Pages 423-430

  Sakai, Hiroyasu ^a   Yamada, Yasuhiro ^a,b,c   Shimizu, Masahito ^a   Saito, Kuniaki ^d   Moriwaki, Hisataka ^a   Hara, Akira ^a  

^a GIFU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

^c KYOTO UNIVERSITY   (Japan)

^d KYOTO UNIVERSITY   (Japan)

Author keywords

Inflammation related colorectal cancer; Mouse; Tnf

Indexed keywords

APC PROTEIN; BETA CATENIN; CALVASCULIN; CXCL1 CHEMOKINE; CYCLOOXYGENASE 2; DEXTRAN SULFATE; FATTY ACID BINDING PROTEIN 2; INTERLEUKIN 1BETA; INTERLEUKIN 6; LYMPHOTOXIN; MONOCYTE CHEMOTACTIC PROTEIN 1; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOODY DIARRHEA; CANCER GROWTH; CHRONIC INFLAMMATION; COLITIS; COLON CARCINOGENESIS; COLORECTAL CANCER; CONTROLLED STUDY; DISEASE SEVERITY; HISTOPATHOLOGY; INTESTINE CRYPT; MORTALITY; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; UPREGULATION; WEIGHT REDUCTION; ANIMAL; C57BL MOUSE; COLORECTAL TUMOR; GENETICS; IMMUNOLOGY; METABOLISM; MOUSE MUTANT; PATHOLOGY;

MUS;

ANIMALS; CHEMOKINE CCL2; CHEMOKINE CXCL1; COLITIS; COLORECTAL NEOPLASMS; CYCLOOXYGENASE 2; DEXTRAN SULFATE; INTERLEUKIN-1BETA; INTERLEUKIN-6; LYMPHOTOXIN-ALPHA; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77949912764     PISSN: 00092797     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cbi.2010.01.014     Document Type: Article

References (52)

1. Hussain S.P., Hofseth L.J., Harris C.C. Radical causes of cancer. Nat. Rev. Cancer 2003, 3(4):276-285.
2. Lashner B.A., Provencher K.S., Bozdech J.M., Brzezinski A. Worsening risk for the development of dysplasia or cancer in patients with chronic ulcerative colitis. Am. J. Gastroenterol. 1995, 90(3):377-380.
3. Locksley R.M., Killeen N., Lenardo M.J. The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell 2001, 104(4):487-501.
4. Carswell E.A., Old L.J., Kassel R.L., Green S., Fiore N., Williamson B. An endotoxin-induced serum factor that causes necrosis of tumors. Proc. Natl. Acad. Sci. U.S.A. 1975, 72(9):3666-3670.
5. Senzer N., Mani S., Rosemurgy A., Nemunaitis J., Cunningham C., Guha C., Bayol N., Gillen M., Chu K., Rasmussen C., Rasmussen H., Kufe D., Weichselbaum R., Hanna N. TNFerade biologic, an adenovector with a radiation-inducible promoter, carrying the human tumor necrosis factor alpha gene: a phase I study in patients with solid tumors. J. Clin. Oncol. 2004, 22(4):592-601.
6. Moore R.J., Owens D.M., Stamp G., Arnott C., Burke F., East N., Holdsworth H., Turner L., Rollins B., Pasparakis M., Kollias G., Balkwill F. Mice deficient in tumor necrosis factor-alpha are resistant to skin carcinogenesis. Nat. Med. 1999, 5(7):828-831.
7. Suganuma M., Okabe S., Marino M.W., Sakai A., Sueoka E., Fujiki H. Essential role of tumor necrosis factor alpha (TNF-alpha) in tumor promotion as revealed by TNF-alpha-deficient mice. Cancer Res. 1999, 59(18):4516-4518.
8. Scott K.A., Moore R.J., Arnott C.H., East N., Thompson R.G., Scallon B.J., Shealy D.J., Balkwill F.R. An anti-tumor necrosis factor-alpha antibody inhibits the development of experimental skin tumors. Mol. Cancer Ther. 2003, 2(5):445-451.
9. Knight B., Yeoh G.C., Husk K.L., Ly T., Abraham L.J., Yu C., Rhim J.A., Fausto N. Impaired preneoplastic changes and liver tumor formation in tumor necrosis factor receptor type 1 knockout mice. J. Exp. Med. 2000, 192(12):1809-1818.
10. Naylor M.S., Stamp G.W., Balkwill F.R. Investigation of cytokine gene expression in human colorectal cancer. Cancer Res. 1990, 50(14):4436-4440.
11. Popivanova B.K., Kitamura K., Wu Y., Kondo T., Kagaya T., Kaneko S., Oshima M., Fujii C., Mukaida N. Blocking TNF-alpha in mice reduces colorectal carcinogenesis associated with chronic colitis. J. Clin. Invest. 2008, 118(2):560-570.
12. Sano H., Kawahito Y., Wilder R.L., Hashiramoto A., Mukai S., Asai K., Kimura S., Kato H., Kondo M., Hla T. Expression of cyclooxygenase-1 and -2 in human colorectal cancer. Cancer Res. 1995, 55(17):3785-3789.
13. Greten F.R., Eckmann L., Greten T.F., Park J.M., Li Z.W., Egan L.J., Kagnoff M.F., Karin M. IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell 2004, 118(3):285-296.
14. Li Q., Withoff S., Verma I.M. Inflammation-associated cancer: NF-kappaB is the lynchpin. Trends Immunol. 2005, 26(6):318-325.
15. Onizawa M., Nagaishi T., Kanai T., Nagano K., Oshima S., Nemoto Y., Yoshioka A., Totsuka T., Okamoto R., Nakamura T., Sakamoto N., Tsuchiya K., Aoki K., Ohya K., Yagita H., Watanabe M. Signaling pathway via TNF-alpha/NF-kappaB in intestinal epithelial cells may be directly involved in colitis-associated carcinogenesis. Am. J. Physiol. Gastrointest. Liver Physiol. 2009, 296(4):G850-859.
16. Itzkowitz S.H., Yio X. Inflammation and cancer IV. Colorectal cancer in inflammatory bowel disease: the role of inflammation. Am. J. Physiol. Gastrointest. Liver Physiol. 2004, 287(1):G7-17.
17. Kawada M., Arihiro A., Mizoguchi E. Insights from advances in research of chemically induced experimental models of human inflammatory bowel disease. World J. Gastroenterol. 2007, 13(42):5581-5593.
18. Wirtz S., Neufert C., Weigmann B., Neurath M.F. Chemically induced mouse models of intestinal inflammation. Nat. Protoc. 2007, 2(3):541-546.
19. Dieleman L.A., Ridwan B.U., Tennyson G.S., Beagley K.W., Bucy R.P., Elson C.O. Dextran sulfate sodium-induced colitis occurs in severe combined immunodeficient mice. Gastroenterology 1994, 107(6):1643-1652.
20. Tanaka T., Kohno H., Suzuki R., Hata K., Sugie S., Niho N., Sakano K., Takahashi M., Wakabayashi K. Dextran sodium sulfate strongly promotes colorectal carcinogenesis in Apc(Min/+) mice: inflammatory stimuli by dextran sodium sulfate results in development of multiple colonic neoplasms. Int. J. Cancer 2006, 118(1):25-34.
21. Taniguchi T., Takata M., Ikeda A., Momotani E., Sekikawa K. Failure of germinal center formation and impairment of response to endotoxin in tumor necrosis factor alpha-deficient mice. Lab. Invest. 1997, 77(6):647-658.
22. Murray N.R., Weems J., Braun U., Leitges M., Fields A.P. Protein kinase C betaII and PKCiota/lambda: collaborating partners in colon cancer promotion and progression. Cancer Res. 2009, 69(2):656-662.
23. Cooper H.S., Murthy S.N., Shah R.S., Sedergran D.J. Clinicopathologic study of dextran sulfate sodium experimental murine colitis. Lab. Invest. 1993, 69(2):238-249.
24. Shimizu M., Deguchi A., Hara Y., Moriwaki H., Weinstein I.B. EGCG inhibits activation of the insulin-like growth factor-1 receptor in human colon cancer cells. Biochem. Biophys. Res. Commun. 2005, 334(3):947-953.
25. Shimizu M., Deguchi A., Joe A.K., McKoy J.F., Moriwaki H., Weinstein I.B. EGCG inhibits activation of HER3 and expression of cyclooxygenase-2 in human colon cancer cells. J. Exp. Ther. Oncol. 2005, 5(1):69-78.
26. Oyama T., Yamada Y., Hata K., Tomita H., Hirata A., Sheng H., Hara A., Aoki H., Kunisada T., Yamashita S., Mori H. Further upregulation of beta-catenin/Tcf transcription is involved in the development of macroscopic tumors in the colon of ApcMin/+ mice. Carcinogenesis 2008, 29(3):666-672.
27. Shields H.M., Bates M.L., Bass N.M., Best C.J., Alpers D.H., Ockner R.K. Light microscopic immunocytochemical localization of hepatic and intestinal types of fatty acid-binding proteins in rat small intestine. J. Lipid Res. 1986, 27(5):549-557.
28. Sweetser D.A., Hauft S.M., Hoppe P.C., Birkenmeier E.H., Gordon J.I. Transgenic mice containing intestinal fatty acid-binding protein-human growth hormone fusion genes exhibit correct regional and cell-specific expression of the reporter gene in their small intestine. Proc. Natl. Acad. Sci. U.S.A. 1988, 85(24):9611-9615.
29. Haegebarth A., Bie W., Yang R., Crawford S.E., Vasioukhin V., Fuchs E., Tyner A.L. Protein tyrosine kinase 6 negatively regulates growth and promotes enterocyte differentiation in the small intestine. Mol. Cell. Biol. 2006, 26(13):4949-4957.
30. Oshima M., Dinchuk J.E., Kargman S.L., Oshima H., Hancock B., Kwong E., Trzaskos J.M., Evans J.F., Taketo M.M. Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell 1996, 87(5):803-809.
31. Szlosarek P.W., Balkwill F.R. Tumour necrosis factor alpha: a potential target for the therapy of solid tumours. Lancet Oncol. 2003, 4(9):565-573.
32. Beutler B.A., Milsark I.W., Cerami A. Cachectin/tumor necrosis factor: production, distribution, and metabolic fate in vivo. J. Immunol. 1985, 135(6):3972-3977.
33. de Kossodo S., Grau G.E., Louis J.A., Muller I. Tumor necrosis factor alpha (TNF-alpha) and TNF-beta and their receptors in experimental cutaneous leishmaniasis. Infect. Immun. 1994, 62(4):1414-1420.
34. Tartaglia L.A., Goeddel D.V. Two TNF receptors. Immunol. Today 1992, 13(5):151-153.
35. Eck M.J., Ultsch M., Rinderknecht E., de Vos A.M., Sprang S.R. The structure of human lymphotoxin (tumor necrosis factor-beta) at 1.9-A resolution. J. Biol. Chem. 1992, 267(4):2119-2122.
36. Browning J., Ribolini A. Studies on the differing effects of tumor necrosis factor and lymphotoxin on the growth of several human tumor lines. J. Immunol. 1989, 143(6):1859-1867.
37. Hohmann H.P., Kolbeck R., Remy R., van Loon A.P. Cyclic AMP-independent activation of transcription factor NF-kappa B in HL60 cells by tumor necrosis factors alpha and beta. Mol. Cell. Biol. 1991, 11(4):2315-2318.
38. Kim M., Miyamoto S., Yasui Y., Oyama T., Murakami A., Tanaka T. Zerumbone, a tropical ginger sesquiterpene, inhibits colon and lung carcinogenesis in mice. Int. J. Cancer 2009, 124(2):264-271.
39. Chaturvedi M.M., Higuchi M., Aggarwal B.B. Effect of tumor necrosis factors, interferons, interleukins, and growth factors on the activation of NF-kappa B: evidence for lack of correlation with cell proliferation. Lymphokine Cytokine Res. 1994, 13(5):309-313.
40. Tanaka T., Suzuki R., Kohno H., Sugie S., Takahashi M., Wakabayashi K. Colonic adenocarcinomas rapidly induced by the combined treatment with 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine and dextran sodium sulfate in male ICR mice possess beta-catenin gene mutations and increases immunoreactivity for beta-catenin, cyclooxygenase-2 and inducible nitric oxide synthase. Carcinogenesis 2005, 26(1):229-238.
41. Tanaka T., Yasui Y., Tanaka M., Oyama T., Rahman K.M. Melatonin suppresses AOM/DSS-induced large bowel oncogenesis in rats. Chem. Biol. Interact. 2009, 177(2):128-136.
42. Kohno H., Takahashi M., Yasui Y., Suzuki R., Miyamoto S., Kamanaka Y., Naka M., Maruyama T., Wakabayashi K., Tanaka T. A specific inducible nitric oxide synthase inhibitor, ONO-1714 attenuates inflammation-related large bowel carcinogenesis in male Apc(Min/+) mice. Int. J. Cancer 2007, 121(3):506-513.
43. Present D.H., Rutgeerts P., Targan S., Hanauer S.B., Mayer L., van Hogezand R.A., Podolsky D.K., Sands B.E., Braakman T., DeWoody K.L., Schaible T.F., van Deventer S.J. Infliximab for the treatment of fistulas in patients with Crohn's disease. N. Engl. J. Med. 1999, 340(18):1398-1405.
44. Hanauer S.B., Feagan B.G., Lichtenstein G.R., Mayer L.F., Schreiber S., Colombel J.F., Rachmilewitz D., Wolf D.C., Olson A., Bao W., Rutgeerts P. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002, 359(9317):1541-1549.
45. Su C., Salzberg B.A., Lewis J.D., Deren J.J., Kornbluth A., Katzka D.A., Stein R.B., Adler D.R., Lichtenstein G.R. Efficacy of anti-tumor necrosis factor therapy in patients with ulcerative colitis. Am. J. Gastroenterol. 2002, 97(10):2577-2584.
46. de Ridder L., Escher J.C., Bouquet J., Schweizer J.J., Rings E.H., Tolboom J.J., Houwen R.H., Norbruis O.F., Derkx B.H., Taminiau J.A. Infliximab therapy in 30 patients with refractory pediatric crohn disease with and without fistulas in The Netherlands. J. Pediatr. Gastroenterol. Nutr. 2004, 39(1):46-52.
47. Rutgeerts P., Van Assche G., Vermeire S. Optimizing anti-TNF treatment in inflammatory bowel disease. Gastroenterology 2004, 126(6):1593-1610.
48. Brooklyn T.N., Dunnill M.G., Shetty A., Bowden J.J., Williams J.D., Griffiths C.E., Forbes A., Greenwood R., Probert C.S. Infliximab for the treatment of pyoderma gangrenosum: a randomised, double blind, placebo controlled trial. Gut 2006, 55(4):505-509.
49. Swaminath A, Lichtiger S. Dilation of colonic strictures by intralesional injection of infliximab in patients with Crohn's colitis. Inflamm. Bowel Dis. 2008, 14(2):213-216.
50. Knight D.M., Trinh H., Le J., Siegel S., Shealy D., McDonough M., Scallon B., Moore M.A., Vilcek J., Daddona P., et al. Construction and initial characterization of a mouse-human chimeric anti-TNF antibody. Mol. Immunol. 1993, 30(16):1443-1453.
51. Scallon B.J., Moore M.A., Trinh H., Knight D.M., Ghrayeb J. Chimeric anti-TNF-alpha monoclonal antibody cA2 binds recombinant transmembrane TNF-alpha and activates immune effector functions. Cytokine 1995, 7(3):251-259.
52. Siegel S.A., Shealy D.J., Nakada M.T., Le J., Woulfe D.S., Probert L., Kollias G., Ghrayeb J., Vilcek J., Daddona P.E. The mouse/human chimeric monoclonal antibody cA2 neutralizes TNF in vitro and protects transgenic mice from cachexia and TNF lethality in vivo. Cytokine 1995, 7(1):15-25.